Newsroom
Sorted by: Latest
-
Object First Earns Dual Honors for Innovation in Data Security and Ransomware Protection
DENVER--(BUSINESS WIRE)--Object First, the ransomware-proof on-premises backup storage company, today announced that it has received two prestigious cybersecurity awards celebrating its innovation and commitment to protecting organizations against ransomware attacks. The company was named the winner in the “Data Security” category of Cyber Defense Magazine’s 2026 Top InfoSec Innovators Awards and was voted “Ransomware Protection and Recovery Company of the Year” in the 18th annual Computing Sec...
-
Sierra Bancorp Reports Record Quarterly Income
PORTERVILLE, Calif.--(BUSINESS WIRE)--Sierra Bancorp Reports Record Quarterly Income...
-
Town Lane Raises $1.9 Billion for Second Real Estate Investment Fund
NEW YORK--(BUSINESS WIRE)--Town Lane Raises $1.9 Billion for Second Real Estate Investment Fund...
-
Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of Directors
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation ARTEMIS® T-cell therapies for the treatment of cancer and autoimmune diseases, today announced the appointment of Cynthia Pussinen as Chief Executive Officer and Chairperson of its Board of Directors, effective October 25, 2026. Ms. Pussinen succeeds Cheng Liu, Ph.D., as Chief Executive Officer. Dr. Liu has been appo...
-
AtriCure to Participate at Upcoming Investor Conferences
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in two upcoming investor conferences. AtriCure’s management is scheduled to participate in a fireside discussion on Monday, November 9, 2026, at 11:00 a.m. Eastern Standard Time at the UBS Global Healthcare Conference....
-
Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to <12 Years with Fibrodysplasia Ossificans Progressiva
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Patients Aged 6 to <12 Years with FOP...
-
Fundway and Monex Partner to Bring FX and Currency Infrastructure to Fund Managers
BRATISLAVA, Slovakia--(BUSINESS WIRE)--Fundway (fundwayplatform.com), the free platform connecting fund managers with verified service providers, today announced a partnership with Monex, a leading specialist in private markets FX and currency infrastructure. Fund managers, whether preparing to launch or already running a fund, can now request an offer from Monex on Fundway. "Since launching in August, we have received dozens of inquiries globally and onboarded two additional service providers,...
-
Coincheck Group N.V. to Announce Second Quarter 2027 Financial Results on November 9, 2026
AMSTERDAM--(BUSINESS WIRE)--Coincheck Group N.V. (NASDAQ: CNCK), a Dutch limited liability company that provides digital asset trade execution, custody, staking and asset management services, today announced that it plans to release its financial results for the quarter ended September 30, 2026, on Monday, November 9, 2026. The company will host a conference call to discuss the quarter at 5:00 pm ET that same day. Hosting the call will be Pascal St-Jean, Chief Executive Officer, and Jason Sandb...
-
C.H. Robinson Debuts Lean AI for Ocean Shipping, Air Freight and Customs
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--C.H. Robinson Debuts Lean AI for Ocean Shipping, Air Freight and Customs...
-
Vyome Co-Founder Dr. Shiladitya Sengupta Promoted to Professor at Harvard Medical School
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (Nasdaq: HIND) ("Vyome"), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today congratulated its Scientific Co-Founder and Director, Dr. Shiladitya Sengupta, PhD, on his promotion to Professor of Medicine at Harvard Medical School. The academic recognition marks an important milestone in Dr. Sengupta’s distinguished scientific career, spanning biomedical research, nanomedicine, bioeng...